← Back to Patent Explorer
US5242950A Expired / Lapsed US ⏱️ 0.0 years remaining

Treatment of macular degeneration

Assignee: Somerset Pharmaceuticals Inc
•
Filing: 1992-04-23
•
Granted: 1993-09-07
•
Expires: 2012-04-23
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method of treating macular degeneration is disclosed which comprises administering to a patient suffering from the disease a therapeutically effective amount of L-deprenyl or a pharmaceutically acceptable acid addition salt thereof for a period of time sufficient to ameliorate the disease.

Inventors

  • 👤 Barbara A. Fries Hastings

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 15:40
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61P; A61P27/00; A61P27/02

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 30 words
A method of treating macular degeneration in a human patient which comprises administering to said patient a therapeutically effective amount of L-deprenyl or a pharmaceutically acceptable acid addition salt thereof.
Claim 2
Independent Claim 30 words
A method of treating macular degeneration in a human patient which comprises administering to said patient a therapeutically effective amount of L-deprenyl or a pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim 16 words
The method according to claim 1 in which L-deprenyl or a salt thereof is administered orally.
Claim 4
Dependent Claim 28 words
The method according to claim 2 in which L-deprenyl or a salt thereof is administered at a dosage of from about 5 to about 15 mg per day.
Claim 5
Dependent Claim 16 words
The method according to claim 1 in which L-deprenyl or a salt thereof is administered transdermally.
Claim 6
Dependent Claim 28 words
The method according to claim 4 in which L-deprenyl or a salt thereof is administered at a dosage of from about 5 to about 50 mg per day.

References Cited (Backward Citations)

US4925878A Cited
US4861800A Cited
US4868218A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1996-09-06 1997-03-08 1997-09-07 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2000-09-06 2001-03-08 2001-09-07 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2004-09-06 2005-03-08 2005-09-07 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag